Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Non-Current Debt (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Non-Current Debt data on record, last reported at $378.8 million in Q4 2025.

  • For Q4 2025, Non-Current Debt rose 18.59% year-over-year to $378.8 million; the TTM value through Dec 2025 reached $378.8 million, up 18.59%, while the annual FY2025 figure was $378.8 million, 18.59% up from the prior year.
  • Non-Current Debt reached $378.8 million in Q4 2025 per CAI's latest filing, up from $376.3 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $378.8 million in Q4 2025 and bottomed at $319.4 million in Q4 2024.